Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK0524A-011 | |||
| 2007_618 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone.
Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood glucose.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Comparator: niacin / Duration of Treatment: 17 Weeks | Drug | |||
| MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks | Drug | |||
| Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the effect of MK0524A on lipids and blood glucose | 17 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| To establish the dose for limiting flushing symptoms induced by NIASPAN (R) | 17 Weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18308010 | Background | Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 1;101(5):625-30. doi: 10.1016/j.amjcard.2007.10.023. Epub 2007 Dec 21. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005483 | Flushing |
| ID | Term |
|---|---|
| D012877 | Skin Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000081206 | Duration of Therapy |
| D009525 | Niacin |
| C518174 | MK-0524 |
| ID | Term |
|---|---|
| D005791 | Patient Care |
| D013812 | Therapeutics |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D009539 | Nicotinic Acids |
| D000147 | Acids, Heterocyclic |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |